To explore the anti-tumor effect of SHR2554, the proliferation of four DLBCL cell lines (EZH2 MT: SU-DHL-6, KARPAS-422; EZH2 WT: U2932, SU-DHL-16) was first analyzed using the cell viability assay. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.